PubAg

Main content area

Effectiveness of pneumococcal Haemophilus influenzae protein D conjugate vaccine against pneumonia in children: A cluster-randomised trial

Author:
Kilpi, T.M., Jokinen, J., Puumalainen, T., Nieminen, H., Ruokokoski, E., Rinta-Kokko, H., Traskine, M., Lommel, P., Moreira, M., Ruiz-Guinazu, J., Borys, D., Schuerman, L., Palmu, A.A.
Source:
Vaccine 2018 v.36 no.39 pp. 5891-5901
ISSN:
0264-410X
Subject:
Haemophilus influenzae, X-radiation, burden of disease, chest, childhood, children, confidence interval, hepatitis, hospitals, infants, otitis media, patients, pneumonia, vaccination, vaccines
Abstract:
Pneumococcal conjugate vaccines have potential to prevent significant proportion of childhood pneumonia. Finnish Invasive Pneumococcal disease vaccine trial was designed to assess the vaccine effectiveness (VE) of the 10-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against several outcomes. We now report results for pneumonia.In this nationwide, cluster-randomised, double-blind trial, children younger than 19 months received PHiD-CV10 in 52 clusters or hepatitis vaccines as control in 26 clusters. Infants younger than 7 months at the first vaccination received either 3+1 or 2+1 vaccination schedule, children aged 7–11 months received 2+1, and those 12–18 months of age two-dose schedule. All hospitalizations and outpatient visits to hospital associated with ICD-10 codes compatible with pneumonia were identified through the National Care Register and 1–3 frontal chest X-ray images per event were collected. External readers who were unaware of the patients’ vaccination status retrospectively interpreted the images. The evaluated outcomes were hospital-diagnosed, hospital-treated pneumonia as primary diagnosis, and radiologically confirmed pneumonia during the blinded, intention-to-treat follow-up period from the first vaccination to the end of 2011. Total VE was calculated as 1 minus rate ratio of all pneumonia episodes.47 366 children were enrolled from February 2009, to October 2010. VE against all episodes of hospital-diagnosed pneumonia was 27% (95% confidence interval [CI]: 14%, 38%), 32% (95% CI: 3%, 52%), and 23% (95% CI: −5%, 44%) in subjects enrolled at age <7, 7–11, and 12–18 months, respectively. Corresponding rate reductions were 3.4, 4.7, and 2.5 per 1000 person-years. VE estimates against pneumonia with alveolar consolidation or pleural effusion (WHO criteria) in the three cohorts were 45% (95% CI: 26%, 60%), 56% (95% CI: 14%, 77%), and 48% (95% CI: 2%, 73%), respectively.PHiD-CV10 vaccination remarkably reduced disease burden due to pneumonia in infants and young children.Main trial NCT00861380, nested carriage and otitis media trial NCT00839254 (ClinicalTrials.gov).
Agid:
6160363